During Wednesday’s Current trade, Shares of Biogen Inc (NASDAQ:BIIB), gain 0.33% to $309.77.
Biogen (BIIB) declared a contract to exclusively license MT-1303, a late stage experimental medicine with potential in multiple autoimmune indications, from Mitsubishi Tanabe Pharma Corporation (MTPC) (TSE:4508). MT-1303 is an oral compound that targets the sphingosine 1-phosphate (S1P) receptor.
Biogen is assessing the potential of MT-1303 in multiple sclerosis (MS), ulcerative colitis, Crohn’s disease, and other autoimmune indications. The compound has accomplished a successful Phase 2 clinical trial in MS and Biogen is evaluating a rapid development program in this indication. The company will also investigate indications in inflammatory bowel disease. Biogen will initiate a clinical trial in ulcerative colitis and may advance an existing program in Crohn’s disease to Phase 3.
Biogen Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurological, autoimmune, and hematologic disorders in the United States and internationally. It provides AVONEX to treat relapsing multiple sclerosis (MS); TYSABRI to treat relapsing forms of MS and Cohn’s disease; PLEGRIDY to treat relapsing MS; TECFIDERA to treat MS; FAMPYRA to improve walking in adult patients with MS; ALPROLIX to treat hemophilia B; ELOCTATE to treat hemophilia A; RITUXAN for treating non-Hodgkin’s lymphoma, rheumatoid arthritis, and chronic lymphocytic leukemia (CLL), in addition to two forms of ANCA-associated vasculitis; GAZYVA for the treatment of patients with formerly untreated CLL; and FUMADERM to treat severe plaque psoriasis in adult patients.
Shares of Deutsche Bank AG (USA) (NYSE:DB), declined -0.20% to $29.43, during its current trading session.
Deutsche Asset & Wealth Administration’s (Deutsche AWM) Alternatives and Real Assets (ARA) business recently declared that it has attained the Wicker Park Commons shopping plaza in Chicago, IL, for one of its investment funds.
Located at 1265-1303 North Milwaukee Avenue, Wicker Park Commons is an urban infill Class-A shopping center with strong credit tenancy, anchored by a dominant grocer and national home improvement store.
Deutsche Bank AG provides investment, financial, and related products and services worldwide. Its Corporate Banking & Securities division engages in selling, trading, and structuring a range of fixed income, equity, equity-linked, foreign exchange, and commodities products. This division also provides mergers and acquisitions, equity and debt financing, and general corporate finance advice, in addition to various financial services to public sector.
Starwood Hotels & Resorts Worldwide Inc (NYSE:HOT), during its Wednesday’s current trading session gained 0.79% to $72.52.
Sheraton Hotels & Resorts recently launched a $100 million multi-channel marketing campaign, which comprises its first comprehensive advertising effort since 2011 and marks the brand’s return to TV for the first time in nearly a decade. Titled “Where Actions Speak Louder,” the new campaign, which is slated to run through 2017, is designed to boldly communicate ongoing enhancements to the Sheraton guest experience, counting new products and partnerships, a renewed focus on service, and an elevated look, feel and design for the flagship brand of Starwood Hotels & Resorts Worldwide, Inc. (HOT).
Starwood Hotels & Resorts Worldwide, Inc., together with its auxiliaries, operates as a hotel and leisure company worldwide. The company owns, operates, and franchises luxury and upscale full-service hotels, resorts, residences, retreats, select-service hotels, and extended stay hotels under the St. Regis, The Luxury Collection, W, Westin, Le Méridien, Sheraton, Four Points, Aloft, and Element brand names.
Finally, Lam Research Corporation (NASDAQ:LRCX), decreased -2.35%, to $70.92.
Lam Research Corporation (LRCX) declared that its Board of Directors has approved a quarterly dividend of $0.30 per share of common stock. On an annualized basis, this will return about $190 million to stockholders based on shares outstanding as of June 28, 2015. The dividend payment will be made September 30, 2015 to holders of record on September 9, 2015. Future dividend payments are subject to review and approval by the Board of Directors.
Lam Research Corporation designs, manufactures, markets, refurbishes, and services semiconductor processing systems used in the fabrication of integrated circuits. It provides thin film deposition products, counting SABRE electrochemical deposition products for copper damascene manufacturing; ALTUS systems to deposit conformal atomic layer films for tungsten metallization applications; VECTOR plasma-improved chemical vapor deposition and atomic layer deposition systems to deposit oxides, nitrides, carbides, multiple patterning films, anti-reflective layers, multi-layer stack films, and diffusion barriers; SPEED high-density plasma-chemical vapor deposition products for applications in shallow trench isolation, pre-metal dielectrics, inter-layer dielectrics, inter-metal dielectrics, and passivation layers; and SOLA ultraviolet thermal processing products for the treatment of back-end-of-line low-k dielectric films and front-end-of-line silicon nitride strained films.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
